Increase in “Null” Cells in Acute Lymphocytic Leukemia in Remission on Long-Term Immunotherapy

  • R. R. Joseph
  • D. Belpomme
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 56)


In the last decade, many reports have attested to the clinical benefits of immunotherapy in the treatment of malignant diseases. Extensive reviews of these publications have recently appeared (6, 12). Although experimental evidence regarding the mechanism of action of BCG and/or inactivated tumor cells on animal immune systems is abundant (7, 8, 11, 13, 15), consistent data in humans is still scanty.


Acute Lymphocytic Leukemia Chemotherapy Group Null Cell Lymphoid Leukemia Acute Lymphoid Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Belpomme, D., Dantchev, D., Du Rusquec, E., Grandjon, D., Huchet, R., Pouillart, P., Schwarzenberg, L., Amiel, J.L., Mathé, G.: T and B lymphocyte markers on the neoplastic cell of 20 patients with acute and 10 patients with chronic lymphoid leukemia. Biomed. 20, 109 (1974)Google Scholar
  2. 2.
    Belpomme, D., Dantchev, D., Joseph, R., Santoro, A., Feuilhade de Chauvin, F., Lelarge, N., Grandjon, D., Ponvert, D., Mathé, G.: Classification of leukemias and hematosarcomas based on cell membrane markers and scanning electron microscopy. In: Clinical tumour immunology. Oxford: Pergamon Press, 1976, Vol. I, p. 131Google Scholar
  3. 3.
    Bentwich, Z., Douglas, S.D., Siegal, F.P., Kunkel, H.G.: Human lymphocyte-sheep erythrocyte rosette formation: some characteristics of the interaction. Clin. Immunol. Immunoth. Pathol. 1, 511–522 (1973)Google Scholar
  4. 4.
    Carosella, E.D., Mochanko, K., Brown, M.: Rosette forming T-cells in human peripheral blood at different ages. Cell Immunol. 12, 323–325 (1974)PubMedCrossRefGoogle Scholar
  5. 5.
    Greenberg, A.H., Hudsen, L., Shen, L., Roitt, I.M.: Antibody-dependent cell-mediated cytotoxicity due to a “null” lymphoid cell. Nature (New Biol.) 242, 111 (1973)CrossRefGoogle Scholar
  6. 6.
    Guttermann, J.U., Navligit, G.M., Reed, R.C., Hersh, E.M.: Immuno-chemotherapy of human cancer. Seminars in Oncology 1, 409 (1974)Google Scholar
  7. 7.
    Halpern, B.N., Biozzi, G., Stiffel, C., Mouton, D.: Effet de la stimulation du système réticulo-endothélial par l’inoculation du bacille Calmette-Guérin sur le développement de l’épithélioma atypique T-8 de Guérin chez le rat. C.R. Soc. Biol. Paris, 153, 919 (1959)PubMedGoogle Scholar
  8. 8.
    Mackaness, G.B., Auclair, D.J., Lagrande, P.H.: Immunopotentiation with BCG I. Immune response to different strains and preparations. J. Nat. Cancer Inst. 51, 1655 (1973)PubMedGoogle Scholar
  9. 9.
    Mac Lennan, I.C.M.: Immunosuppression and immunostimulation in acute leukemia. Proc. Roy. Soc. Med. 68, 216 (1975)Google Scholar
  10. 10.
    Mathé, G., Amiel, J.L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J.R., Hayat, M., De Vassal, F.: Active immunotherapy for acute lymphoid leukemia. Lancet 1, 697 (1969)PubMedCrossRefGoogle Scholar
  11. 11.
    Mathé, G., Kamel, M., Dezfulian, M., Halle Pannenko, Bourut, C.: An experimental screening for “systemic adjuvands of immunity” applicable in cancer immunotherapy. Cancer Res. 33, 1987 (1973)PubMedGoogle Scholar
  12. 12.
    Nathanson, L.: Use of BCG in the treatment of human neoplasms: a review. Seminars in Oncology 1, 337 (1974)PubMedGoogle Scholar
  13. 13.
    Old, L.J., Benacerraf, B., Clarke, D.A., Carswell, E.A., Stockert, E.: The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res. 21, 1281–1300 (1961)PubMedGoogle Scholar
  14. 14.
    Pouillart, P., Palangie, T., Schwarzenberg, L., Brugerie, E., Lheritier, J., Mathé, G.: Effect of BCG on hematopoietic stem cells: experimental and clinical study. Cancer Immunol. Immunoth., in press (1976)Google Scholar
  15. 15.
    Reif, A.E., Kim, C.A.H.: Leukemia L1210 therapy trials with anti-leukemia serum and Bacillus Calmette-Guerin. Cancer Res. 31, 1606–1612 (1971)PubMedGoogle Scholar
  16. 16.
    Sen, L., Borella, L.: Expression of cell surface markers on T and B lymphocytes after long-term chemotherapy of acute leukemia. Cell. Immunol. 9, 84 (1973)PubMedCrossRefGoogle Scholar
  17. 17.
    Weksler, M.E., Hutteroth, .: Impaired lymphocyte function in aged humans. J. Clin. Invest. 53, 99–104 (1974)PubMedCrossRefGoogle Scholar
  18. 18.
    W.H.O./I.A.R.C. Workshops: Special technical report. Identification, enumeration and isolation of B and T lymphocytes from human peripheral blood. Scand. J. Immunol. 3, 521 (1974)CrossRefGoogle Scholar
  19. 19.
    Wybran, J., Fudenberg, H.: How clinically useful is T and B cell quantitation? Ann. Int. Med. 80, 765 (1974)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1976

Authors and Affiliations

  • R. R. Joseph
  • D. Belpomme

There are no affiliations available

Personalised recommendations